Navigation Links
Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
Date:10/29/2007

Optivus Proton Therapy, Inc. Teams with Parsons Commercial Technology Group

Inc. to Produce Proton Beam Treatment Centers Globally

LOS ANGELES, Oct. 29 /PRNewswire/ -- Yesterday, at the 49th Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), Optivus Proton Therapy, Inc. (Optivus(R)) and Parsons Commercial Technology Group Inc., a global business unit of Parsons Corporation, announced a historic teaming agreement has been formalized between the two companies to globally produce turn-key proton beam therapy centers.

"The agreement between the teams of Optivus and Parsons will assure our clients that their proton system will be completed on time by the most expert team in the field," said Jon Slater, Optivus President and CEO. "This is a win/win/win situation for Optivus, Parsons and our clients."

Founded in 1944, Parsons is one of the largest 100% employee-owned management, engineering, and construction companies in the United States.

"Parsons collaborates with innovators and leaders in many diversified markets. We are thrilled to add the development of proton beam therapy centers, with Optivus, to our wide-ranging portfolio," said John Small, Parsons Group President.

Optivus was formed by the engineers who designed and installed the world's first and most successful hospital-based proton center at Loma Linda University Medical Center in Loma Linda, California. The facility commissioned and maintained by Optivus has enjoyed more success than all other comparable competitors' systems, with higher throughput, the most patients treated, and the most types of diseases treated with the most reliable and efficient device on the market.

"Interest in the development of proton treatment centers has grown at an enormous rate in recent years and can largely be attributed to our successes," Slater said. "This development will further reinforce our position as the global leader in proton therapy technology," he added.

The Southern California-based Optivus Parsons team will meet the market demand for the development of proton therapy using Optivus' patented and proven technology.

"The global success and leadership of Parsons guarantees our ability to develop multiple proton centers simultaneously with a consistent level of resources and integrity," said Slater.

"The Optivus Parsons teaming agreement is a milestone for both companies," said Small. "We share Optivus' dedication and commitment to patients who will benefit from the life-saving proton treatment technology for which they've set the gold standard."

Representatives from Parsons will be in attendance at the Optivus booth 501 during ASTRO for Q & A.

ABOUT OPTIVUS AND PARSONS

Optivus Proton Therapy, Inc. is a pioneer in the field of proton therapy technology. Optivus' patented, FDA-cleared modular Proton Beam Therapy System (PBTS), the Conforma 3000(R), leads the industry in patient throughput, highest operational reliability and safety. To date, the Optivus system has delivered nearly half a million individual patient treatments with a perfect safety record. For more information about Optivus, visit http://www.optivus.com.

Parsons, celebrating more than 60 years of setting industry standards, is a leader in many diversified markets such as healthcare, education and public buildings, infrastructure, water, transportation, construction, planning, commercial, industrial manufacturing, communications, environmental, life sciences, critical facilities, nuclear and special materials, and homeland security. Parsons provides technical and management solutions to private industrial customers worldwide, as well as federal, regional, and local government agencies. For more information about Parsons, visit http://www.parsons.com.

Contact:

Lisa Pizzi

Marketing Communications

Optivus Proton Therapy, Inc.

909.799.8367 tel.

lpizzi@optivus.com

John Small

Parsons Group President

704.558.4124 tel.

john.small@parsons.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Optivus Proton Therapy, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
2. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
5. Historic trial for tuberculosis launched together by leading drug companies
6. Historic Increase In Incidence Of Sexually Transmitted Diseases In Scotland
7. Micro-world of Prehistoric Bacteria Found in Amber
8. Black-Owned Hospital Receives Historical Commemorative Marker
9. Agreement To Speed Up Development of Bird flu vaccine
10. MIOT Hospital Signs Agreement With German Healthcare Facility
11. Indo-Fiji Agreement in Field of Health, Medicine Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: